In:
Blood Advances, American Society of Hematology, Vol. 2, No. 13 ( 2018-07-10), p. 1532-1540
Abstract:
Low-dose cytarabine treatment reduced mortality in symptomatic TMD patients compared with the historical control. An MRD monitoring–based low-dose cytarabine treatment does not prevent progression from preleukemic TMD to ML-DS.
Type of Medium:
Online Resource
ISSN:
2473-9529
,
2473-9537
DOI:
10.1182/bloodadvances.2018018945
Language:
English
Publisher:
American Society of Hematology
Publication Date:
2018
detail.hit.zdb_id:
2876449-3